Long-term follow-up of patients developing gastric mucosal lesions after initiating the potassium-competitive acid blocker vonoprazan

참고문헌

1. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 2012; 55:4446-4456.
2. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 2005;14:411-421.
3. Matsukawa J, Kogame A, Tagawa Y, et al. Radiographic localization study of a novel potassium-competitive acid blocker, vonoprazan, in the rat gastric mucosa. Dig Dis Sci 2016;61:1888-1894.
4. Miyamoto S, Matsuno Y, Kato M, et al. Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan. Am J Gastroenterol 2017;112:1899-1901.
5. Kubo K, Kimura N, Matsuda S, et al. Vonoprazan-associated gastric mucosal redness: a report of four cases. Intern Med 2020;59:507-511.
6. Kubo K, Kimura N, Watanabe R, et al. Vonoprazan-associated gastric mucosal redness in non-Helicobacter pylori-infected and Helicobacter pylori-eradicated stomach. Case Rep Gastroenterol 2021;15:751-758.
7. Nishiyama N, Kobara H, Ayaki M, et al. White spot, a novel endoscopic finding, may be associated with acid-suppressing agents and hypergastrinemia. J Clin Med 2021;10:2625.
8. Yoshizaki T, Morisawa T, Fujinami M, et al. Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan. Aliment Pharmacol Ther 2021;53:94-102.
9. Iwamuro M, Shiraha H, Okada H. Gastric polyps' regression after potassium-competitive acid blocker cessation. J Gen Fam Med 2022;23:358-359.
10. Goto C, Okimoto K, Matsusaka K, et al. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding. Clin J Gastroenterol 2023;16:159-163.